Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.

Darren M. Kocs, A. Mark Fendrick

PubMed · 2003 · 39 citations · 24 references

Abstract

The off-label use of rituximab is substantial. Projections of oncology-related patterns of care and drug expenditures must account for the potential for off-label use.

References

24